Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

A nail in the coffin for DNA sequence patents?

Does the recent Board decision in Ex parte Kubin mean the end for biotech patents claiming DNA sequences?

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ex parte Kubin, 83 USPQ2d 1410 (Bd. Pat. App. & Int. 2007).

  2. Kubin, et al. Eur. J. Immunol. 29, 3466–3477 (1999).

    Article  CAS  PubMed  Google Scholar 

  3. US Patent No. 5,688,690 (1997).

  4. Sambrook, J., Fritsch, E. & Maniatis, T. Molecular Cloning: A Laboratory Manual, edn. 2 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

    Google Scholar 

  5. Mathew, P.A. et al. J. Immunol. 151, 5328–5337 (1993).

    CAS  PubMed  Google Scholar 

  6. In re Deuel, 51 F.3d 1552 (Fed. Cir. 1995).

  7. KSR International Co. v. Teleflex Inc., 550 U.S.___, 127 S.Ct. 1727 (2007).

  8. Teitelbaum, R. & Cohen, M. Nat. Biotechnol. 25, 1105–1106 (2007).

    Article  CAS  PubMed  Google Scholar 

  9. Federal Register 72, 57526–57535 (2007).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamanaka, M. A nail in the coffin for DNA sequence patents?. Nat Biotechnol 26, 1085–1086 (2008). https://doi.org/10.1038/nbt1008-1085

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1008-1085

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing